No Data
No Data
環球醫療:本集團未經審核二零二四年第一季度營運概要
環球醫療:年度報告2023
Global Healthcare (02666.HK) completed the issuance of 500 million yuan of renewable corporate bonds
On April 22, GLONGHUI (02666.HK) announced that China Global Leasing Co., Ltd. (the “Issuer”), a wholly-owned subsidiary of the company, will issue the first renewable corporate bonds in 2024 in China. The issuance of the current corporate bonds was completed in China on April 22, 2024. The total principal amount of the current corporate bonds issued is RMB 500 million. The base period is 3 years from April 22, 2024, and the fixed interest rate is 2.99%. At the end of the agreed base period and at the end of each renewal cycle, the issuer has the right to exercise the right to renew. The issue price is RMB per bond
Global Healthcare (02666.HK) subsidiary plans to issue renewable corporate bonds of no more than 500 million yuan
Global Healthcare (02666.HK) announced that China Global Leasing Co., Ltd. (issuer), a wholly-owned subsidiary of the company, has received approval from the China Securities Regulatory Commission (CSRC) to publicly issue domestic renewable corporate bonds with a total principal amount of up to RMB 2 billion to qualified investors in China. The remaining amount as of the date of this announcement is RMB 2 billion. The bonds were issued in instalments, and the total principal amount issued this time was no more than RMB 500 million (including RMB 500 million).
Professional and industrial net profit surged 271.8%, and Global Healthcare (2666.HK) can be expected to grow rapidly
As the overall development strategy continues to be implemented, supported by multiple advantages such as stable fundamentals and sufficient funding, it is worth looking forward to the explosive growth of global healthcare in the future.
China Post Securities: Endogenous growth is steady, and the Hong Kong stock healthcare services sector's valuation is highly attractive
Judging from the overall performance of medical service targets in Hong Kong stocks, with the exception of ICL's high revenue base in the early COVID-19 period, where dental revenue was affected by dental implant collection, most of the revenue from other medical service targets increased relatively well.
No Data